|FOR IMMEDIATE RELEASE:|
December 20, 2012
Phone: (571) 483-1379
ALEXANDRIA, Va. - The Conquer Cancer Foundation of the American Society of Clinical Oncology (ASCO) today announced the recipients of its 2013 Merit Awards in Genitourinary Cancer, which recognize oncology professionals for their research in the area of genitourinary cancers. The Foundation will honor 25 award recipients at the 2013 Genitourinary Cancers Symposium taking place February 14-16 in Orlando.
“The innovative and promising research of our awardees steadily grows our fundamental and clinical understanding of cancer. These studies will enable oncologists to provide cancer patients with evidence-based improved care,” said Martin J. Murphy, DMedSc, PhD, Chair of the Conquer Cancer Foundation of ASCO Board of Directors. “The Conquer Cancer Foundation is proud to recognize our 2013 Merit Awardees who have earned both our gratitude and our admiration for their personal commitment to cancer patients through their pioneering research.”
This year’s Symposium will feature research advances on the treatment and management of a variety of genitourinary cancers, including cancers of the bladder, kidneys, penis, prostate, testis and urethra. The Conquer Cancer Foundation of ASCO Merit Awards are designed to promote clinical cancer research in these areas by providing the opportunity for recipients to present their findings at the Symposium.
The 2013 Merit Award in Genitourinary Cancer recipients and their abstracts are:
- Ayal Aizer, MD, Brigham and Women’s Hospital, Massachusetts General Hospital
Multidisciplinary care and management of very low-risk prostate cancer.
- Shaheen Alanee, MD, MPH, Memorial Sloan-Kettering Cancer Center
Exome sequencing of extreme phenotypes to identify variants predictive of response to chemotherapy in bladder cancer.
- Christine Barnett, MD, Oregon Health and Science University
Genomic analysis of prostate cancer.
- Maristella Bianconi, MD, Scoula di Specializzazione in Oncologia, Universita Politecnica dellle Marche
Effect of VEGF and VEGFR polymorphisms on clinical outcome and response in patients with advanced renal cell carcinoma receiving first-line treatment.
- Elena Castro, MD, PhD, The Institute of Cancer Research and The Royal Marsden NHS Foundation Trust
Effect of germ-line BRCA mutations in biochemical relapse and survival after treatment for localized prostate cancer.
- Henry Conter, MD, MSc, The University of Texas MD Anderson Cancer Center
Ten-year follow up of patients with metastatic renal cell carcinoma treated with interferon alfa-2b as first-line therapy: Results from a randomized trial.
- Oussama Darwish, MD, The University of Texas Southwestern Medical Center
Novel stratification of the recurrence risk following surgical extirpation of clear cell renal cell carcinoma using tissue biomarkers in the mammalian target of rapamycin pathway.
- Phillip Gray, MD, Harvard Radiation Oncology Program
Clinical-pathologic stage discrepancy in patients with bladder cancer treated with radical cystectomy: Associations with clinical variables and survival.
- Elizabeth Guancial, MD, Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute
Relationship of ERCC1 genotype variant with mRNA expression and ERCC1 protein levels in advanced urothelial carcinoma.
- Abraham A. Hakimi, MD, Memorial Sloan-Kettering Cancer Center
Association of mutations in chromatin modifiers with poor survival in clear cell renal cell carcinoma: Analysis of the Cancer Genome Atlas Project.
- Mehmet Hepgur, MD, USC Keck School of Medicine, Norris Comprehensive Cancer Center
Changes in circulating tumor cells and markers of inflammation after sipuleucel-T treatment.
- Suneil Jain, PhD, Sunnybrook Health Sciences Centre
Gleason upgrading with time in a large, active surveillance cohort with long-term follow-up.
- Joseph Kim, MD, National Cancer Institute, National Institutes of Health
Safety profile of poxviral vaccines: NCI experience.
- Eugene Lee, MD, The University of Texas MD Anderson Cancer Center
Augmentation of urothelial cancer cells’ response to gemcitabine and cisplatin by a Smac mimetic.
- Marc Matrana, MD, MS, The University of Texas MD Anderson Cancer Center
Outcomes of patients with metastatic renal cell carcinoma treated with pazopanib after progression on other targeted therapies: Updated results.
- Rana R. McKay, MD, Dana-Farber Cancer Institute
Impact of bone and liver metastases in patients with metastatic renal cell carcinoma (mRCC) treated with molecularly targeted agents: Results from the International mRCC Database Consortium.
- Andrea Necchi, MD, Fondazione IRCCS Istituto Nazionale dei Tumori
Modified cisplatin, etoposide, and ifosfamide (PEI) salvage therapy for male germ-cell tumors: Long-term efficacy and safety outcomes.
- Elizabeth O’Donnell, MD, Dana-Farber Cancer Institute
A 10-year retrospective review of germ cell tumors not cured with cisplatin-based chemotherapy.
- Amishi Shah, MD, University of Pennsylvania
Increase in blood pressure with sorafenib exposure in renal cell carcinoma versus other solid tumors.
- Brian Shuch, MD, National Cancer Institute, National Institutes of Health
Defining early-onset kidney cancer: Implications for genetic counseling.
- Swetha Sridharan, MD, Princess Margaret Hospital
Use of radiotherapy for seminoma patients with low-volume infradiaphragmatic nodal disease.
- Robert van Soest, MD, Erasmus University Medical Center
The initial biopsy Gleason score as a predictive marker for docetaxel survival benefit in patients with prostate cancer: Data from the TAX 327 study.
- David VanderWeele, MD, PhD, University of Chicago Medical Center
The molecular relationship among concurrent prostate cancer foci.
- Daniel Willis, MD, The University of Texas MD Anderson Cancer Center
Clinical outcomes in focal versus extensive micropapillary bladder cancer at the time of diagnostic transurethral resection.
- Robert Zielinski, MBBS, Westmead Hospital
Population-based impact on overall survival after the introduction of docetaxel as standard therapy for metastatic castration resistant prostate cancer.
These 2013 Conquer Cancer Foundation of ASCO Merit Awards in Genitourinary Cancer are supported by: Amgen, Lilly USA LLC, Millennium: The Takeda Oncology Company, and Onyx Pharmaceuticals.